Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Aoxing Pharma Receives License for Narcotic Cough Treatment

publication date: Jan 28, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Aoxing Pharma, a China company with a narcotic drugs focus, received an SFDA license to produce the API in pholcodine, an opioid cough suppressant. The company still needs to pass a GMP inspection before it is allowed to market the product. Aoxing owns one of just thirteen narcotics licenses in China. Nevertheless, the company’s revenues for the most recent 12 months were only $9 million, while its loss totaled $15 million. More details....

Stock Symbol: (NYSE MKT: AXN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors